Endovascular thrombectomy (EVT) does not lead to better outcomes at 90 days compared with usual care or best medical t ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company’s ...

Use of endovascular thrombectomy in patients with acute ischemic stroke caused by occlusions in distal vessels has failed to ...

Three trials showed no improvement in functional outcomes, and the potential for harm, versus medical therapy alone.

The clot-dissolving medication, alteplase, improved stroke patients' recovery by more than 50% when given up to 24 hours ...

LOS ANGELES -- For patients with large vessel occlusion (LVO) strokes, researchers found ways to make adjunctive ...

Revalesio updates new analyses from phase 2 RESCUE clinical study of RNS60 in patients with acute ischemic stroke: Tacoma, Washington Friday, February 7, 2025, 18:00 Hrs [IST] Rev ...

In any case, there was no mortality signal associated with alteplase administered up to 24 hours after a stroke in HOPE.

(Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world's first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system-the ...

Intensive BP lowering after successful endovascular thrombectomy for acute anterior circulation ischemic stroke did not improve 90-day functional outcomes vs. standard BP control, a speaker ...

A novel imaging analysis technique registered a high degree of sensitivity and specificity in identifying both presence and ...